PIC Therapeutics, Inc.

PIC Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapeutics that target the Pre-Initiation Complex (PIC), with the aim of selectively inhibiting cancer-causing proteins. Founded in 2016 and based in Natick, US, PIC Therapeutics, Inc. specializes in cancer therapeutics.

The company has engaged in 4 deals, with the latest funding round, Series A, concluded on October 7, 2022, raising USD 6. 47 mn led by OrbiMed Advisors. The current CEO is Katherine Bowdish. PIC Therapeutics develops advanced cancer therapeutics aimed at modulating RNA translation, particularly through the targeting of the Pre-Initiation Complex (PIC).

This approach is designed to inhibit the production of oncogenic proteins, thereby addressing various cancer types. The primary end users of these therapeutics are cancer patients experiencing therapeutic resistance or complex tumor challenges, with a focus on improving outcomes through precision treatment options. PIC Therapeutics operates a revenue model centered around the commercialization of its oncology-focused precision therapeutics. The company is likely to establish partnerships with healthcare providers and research institutions to facilitate product distribution, generating revenue through sales to healthcare facilities and collaborative agreements with shared R&D funding.

Following the recent Series A funding of USD 6. 47 mn in October 2022, led by OrbiMed Advisors, PIC Therapeutics plans to expand its portfolio and focus on developing new products specifically for breast cancer treatment. The funding will support the company's initiatives to grow and potentially enter new oncology markets, enhancing its footprint in the industry.